M MtoZ Biolabs
Home > Support > Resources > Targeted Mass Spectrometry

Targeted Mass Spectrometry

By Frank Mitchell · Published: November 16, 2026

Targeted mass spectrometry remeasures a closed analyte panel with selective liquid chromatography-tandem mass spectrometry (LC-MS/MS) acquisition instead of surveying an open proteome. In proteomics projects, multiple reaction monitoring (MRM) or selected reaction monitoring (SRM) schedules precursor-to-product transitions on a triple quadrupole (Lange et al. 2008). Parallel reaction monitoring (PRM) isolates scheduled precursors on a high-resolution platform and stores product-ion spectra for fragment review (Peterson et al. 2012). The practical project question is whether named peptides must be remeasured under a declared relative or absolute claim, not whether an instrument class sounds more sensitive.

Relative targeted tables answer fold-change under a declared normalization rule. Absolute amount needs matched stable isotope-labeled internal standard (SIS) peptides or Absolute QUAntification (AQUA) design plus a calibration model in the study matrix (Gerber et al. 2003; Carr et al. 2014). Proteotypic surrogates report the measured sequence under the stated digest. They do not invent every isoform or modified form by default (Bantscheff et al. 2012). Discovery data-dependent acquisition (DDA) or data-independent acquisition (DIA) can nominate candidates, but those routes are not interchangeable with a locked targeted method.

In MtoZ Biolabs targeted offerings, targeted mass spectrometry is scoped when panel status, platform preference, claim unit, matrix notes, and deliverable depth are written in the brief. Service intake appears in Targeted Proteomics Service.

What Targeted Mass Spectrometry Covers

Four project layers belong in the brief and stay separated.

Panel layer freezes proteins or proteotypic peptides with priority tiers before acquisition. An open candidate pool is still discovery work.

Platform layer chooses MRM/SRM for stable scheduled transitions, PRM when fragment confirmation is required, or a hybrid design when both are justified.

Claim layer separates relative normalization from SIS-calibrated absolute units.

Deliverable layer names quantified tables, method notes, quality control (QC) summaries, failed-target flags, and any calibration evidence the stakeholder will review.

Targeted mass spectrometry remeasures known panel members under selective acquisition. It does not create an open proteome inventory from the same file.

Definitional framing of the quantitative claim appears in What is Targeted Quantitative Proteomics. Method-family boundaries appear in Overview of Targeted Proteomics: Methods, Techniques, Key Points, and Applications.

How MRM, PRM, and Claim Units Fit Together

Acquisition mode and claim unit should be chosen separately.

MRM/SRM fits high-throughput remeasurement when matrix-matched transition ratios stay stable (Lange et al. 2008). PRM fits peptides that need high-resolution fragment review after precursor isolation (Peterson et al. 2012; Gallien et al. 2012). Hybrid panels keep stable targets on MRM and interference-limited targets on PRM. Platform detail appears in Parallel Reaction Monitoring vs MRM: Which Fits?.

Relative claims need matched preparation and a declared normalization rule. Absolute claims add SIS or AQUA design, calibrators, and recovery QC (Gerber et al. 2003). Absolute versus relative route framing appears in Absolute Protein Quantification or Relative Quantitation? Matching AQUA, MRM/PRM, and Label-Free Routes to Your Reporting Goal. Absolute service intake appears in Absolute Quantitative Analysis (AQUA) Service.

Site-specific modified peptides can enter a targeted panel only when the modified sequence is named, the digest supports it, and interference is reviewed in matrix. Broad post-translational modification discovery is not the same as remeasuring a closed modified-peptide list. Discovery-to-targeted staging appears in Targeted Mass Spectrometry or Discovery LC-MS/MS? Matching MRM, PRM, and Profiling Routes to Your Analytical Goal.

End-to-End Targeted Mass Spectrometry Workflow

A practical comprehensive spine usually runs as follows.

  1. Freeze the decision: relative panel contrast, pathway or biomarker remeasurement, or absolute amount.
  2. Close the analyte list and assign priority tiers with a panel version ID.
  3. Document matrix, pretreatment parity, storage, and expected study plus QC injection count.
  4. Declare relative normalization or SIS/AQUA absolute rules and spike timing.
  5. Choose MRM/SRM, PRM, or a hybrid design from matrix risk and fragment-review need.
  6. Build transitions or fragment rules on matrix-matched digests; run a pilot before full cohort shipment.
  7. Lock one prep method and one acquisition method for the cohort block.
  8. Acquire interleaved study samples with blanks, QC pools, and calibrators when absolute units are required.
  9. Integrate peaks, apply inclusion rules, flag failed targets, and deliver tables with method notes and the declared reporting unit.

Steps 1 through 4 protect the decision and claim. Steps 5 through 9 are the platform, acquisition, and reporting record. MRM/SRM service context appears in SRM-MRM Quantitative Proteomics Services. PRM service context appears in Parallel Reaction Monitoring (PRM) Service. Quote-stage panel and deliverable lock appears in Scoping a Targeted Mass Spectrometry Project: Analyte Panel, Platform, and Validation Deliverables.

Targeted mass spectrometry workflow from panel lock and platform choice through matched prep, QC-inclusive acquisition, and claim-unit delivery

Figure 1. Targeted mass spectrometry is operable only after the panel, platform, claim unit, and QC plan are locked before cohort acquisition.

Parameters That Must Be Locked for Targeted MS Projects

Layer

Parameter that must be declared

Failure mode if ignored

Decision

Relative contrast versus absolute unit

Wrong platform and QC depth

Panel version

Peptide list ID and priority tiers

Mid-cohort panel growth

Platform

MRM/SRM, PRM, or hybrid rationale

Weak transitions forced through one mode

Matrix

Type, storage, pretreatment parity

Suppression read as biology

Cycle time

Retention windows and dwell schedule

Dropped targets on dense panels

SIS or AQUA

Spike step and assigned amount

Amount claim without calibration design

QC plan

Blanks, pools, precision, drift checks

Batch effect unread

Inclusion rules

Failed-target handling

Silent zeros in group means

Deliverable

Table, method notes, reporting unit

Numeric file without assay context

Archive

Method and panel version with report

Untraceable remeasurement later

Limits follow the same table. Targeted mass spectrometry cannot quantify unnamed proteins without peptide selection. A larger panel does not replace a matrix pilot. Relative ratios are not concentrations. Clinical diagnosis, pharmacokinetic release, or precision-medicine language needs a separately validated method beyond a research targeted table.

What Targeted Mass Spectrometry Can Support

A locked relative panel supports same-peptide comparison across samples acquired with one method version. A locked absolute panel supports concentration or amount for surrogates inside the calibrated interval when SIS design and QC recovery are documented.

Biomarker candidate remeasurement and pathway panel tracking are common fit cases after inclusion rules pass. Operational detail for those use cases appears in Targeted Proteomics Workflows for Biomarker and Pathway Quantitation. Failed targets support exclusion or redesign. They do not support silent zeros. Cross-study comparison needs matching normalization or calibration assumptions.

A targeted mass spectrometry package supports the declared panel decision. It does not convert an open proteome into a validated clinical cutoff.

How to Choose Targeted MS Scope for Your Project

Use list status, matrix risk, claim unit, and report use together.

Project signal

Scope that often fits

Recheck before committing

Closed panel, fold-change decision

Relative MRM after matrix pilot

Call ratios concentrations

Closed panel, amount decision

SIS or AQUA design plus calibrators

Relative-only method for ng/mL claims

Interference-limited peptides

PRM or hybrid MRM plus PRM

Force whole panel onto weak transitions

List still open

Discovery DDA or DIA first

Targeted quote on unnamed proteins

Biomarker or pathway remeasurement

Frozen panel version and matched prep

Expand panel mid cohort

Stakeholder needs method and QC notes

Deliverables locked at quote

Rebuild documentation after acquisition

Prior transitions unstable in matrix

Panel redesign or PRM review

Scale the same weak method

Choosing targeted mass spectrometry scope by relative MRM need, absolute or PRM-supported design, or discovery-first staging

Figure 2. Match targeted MS scope to list status and claim unit; keep discovery first when candidates are still unnamed.

Post-delivery interpretation belongs on Reading Targeted Mass Spectrometry Results with Confidence. Teams with panel tiers, matrix notes, platform preference, and deliverable lists can review MtoZ Biolabs Targeted Proteomics Service when those fields are declared in the project record.

Frequently Asked Questions

1. What is targeted mass spectrometry in proteomics projects?

It is selective LC-MS/MS remeasurement of a closed protein or peptide panel, usually by MRM/SRM or PRM, under a declared relative or absolute claim unit.

2. How do MRM and PRM differ in a targeted MS project?

MRM/SRM monitors predefined transitions and fits stable high-throughput panels. PRM stores high-resolution fragment spectra and fits interference-limited targets or hybrid designs.

3. Does targeted mass spectrometry always report absolute concentrations?

No. Relative targeted panels are quantitative for fold-change when normalization and QC are declared. Absolute units require SIS or AQUA design and calibration.

4. Can targeted MS replace discovery profiling?

No. Discovery nominates candidates. Targeted MS remeasures a closed shortlist after names and peptides are versioned.

5. What must be locked before shipping a targeted MS cohort?

Panel version, platform choice, claim unit, matched prep rules, QC plan, and deliverable list.

MtoZ Biolabs can provide targeted mass spectrometry analysis using MRM, PRM, and isotope-assisted absolute quantification for predefined protein or peptide panels, including assay development and QC-supported reporting when panel design and study goals are documented.

If further evaluation of panel staging, MRM versus PRM design, or relative versus absolute claim scope is needed, project details can be submitted for a feasibility review.

Reference

  1. V. Lange, P. Picotti, B. Domon, R. Aebersold (2008). Selected reaction monitoring for quantitative proteomics: a tutorial. Mol. Syst. Biol., 4, 222. https://doi.org/10.1038/msb.2008.61
  2. A.C. Peterson, J.D. Russell, A.A. Klammer, P.F. Doubleday, H. Liu, J.N. Anderson, M.J. MacCoss (2012). Parallel reaction monitoring for high resolution and high mass accuracy quantitative, targeted proteomics. Mol. Cell. Proteomics, 11, 1475-1488. https://doi.org/10.1074/mcp.O112.020271
  3. S. Gallien, E. Duriez, C. Crone, M. Kellmann, T. Moehring, B. Domon (2012). Targeted proteomic quantification on quadrupole-orbitrap mass spectrometer. Mol. Cell. Proteomics, 11, 1709-1723. https://doi.org/10.1074/mcp.O112.019802
  4. S.A. Gerber, J. Rush, O. Stemman, M.W. Kirschner, S.P. Gygi (2003). Absolute quantification of proteins and phosphoproteins from cell lysates by tandem MS. Proc. Natl. Acad. Sci. U.S.A., 100, 6940-6945. https://doi.org/10.1073/pnas.0832254100
  5. S.A. Carr, S.E. Abbatiello, B.L. Ackermann, C. Borchers, B. Domon, E.W. Deutsch, R.P. Grant, A.N. Hoofnagle, R. Huttenhain, J.M. Koomen, D.C. Liebler, T. Liu, B. MacLean, D.R. Mani, E. Mansfield, H. Neubert, A.G. Paulovich, L. Reiter, O. Vitek, R. Aebersold, A.J. Smith, et al. (2014). Targeted peptide measurements in biology and medicine: best practices for sample preparation, assay standardization, and assay validation. Mol. Cell. Proteomics, 13, 907-917. https://doi.org/10.1074/mcp.M113.036095
  6. M. Bantscheff, S. Lemeer, H.U. Haab, B. Kuster (2012). Quantitative mass spectrometry in proteomics: a critical review. Anal. Bioanal. Chem., 404, 939-965. https://doi.org/10.1007/s00216-012-5892-4

Support Documents

Protein Quantification for Deeper Discovery

Gain a clearer understanding of protein quantification approaches and their applications in studying protein abundance changes by downloading our detailed brochure.

Submit the form below to download the
This checkbox is required
* I agree to receive other communications from MtoZ Biolabs, which may contain technical or marketing information. You can unsubscribe from thlese communications at any time.
SUBMIT
 

How to Order

How to Order
Request a Quote

Request a Project Quote

Please complete the required fields below. We will review your information and respond with a tailored recommendation.

Project inquiry

Fields marked with * are required for quote review.

Secure inquiry · No obligation
Required Information

Your information will be used only to respond to your inquiry.

Submit Inquiry